Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 2,377.85
+14.20 (0.60%)
At close: Jun 16, 2026
Caplin Point Laboratories Market Cap
Caplin Point Laboratories has a market cap or net worth of 180.74 billion as of June 16, 2026. Its market cap has increased by 9.50% in one year.
Market Cap
180.74B
Enterprise Value
171.91B
Revenue
21.87B
Ranking
n/a
PE Ratio
28.27
Stock Price
2,377.85
Market Cap Chart
Since February 26, 2002, Caplin Point Laboratories's market cap has increased from 5.60M to 180.74B, an increase of 3,228,055.23%. That is a compound annual growth rate of 53.26%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Jun 16, 2026 | 180.74B | 29.15% |
| Dec 31, 2025 | 139.95B | -26.39% |
| Dec 31, 2024 | 190.12B | 84.60% |
| Dec 29, 2023 | 102.99B | 90.47% |
| Dec 30, 2022 | 54.07B | -16.82% |
| Dec 31, 2021 | 65.01B | 69.50% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro |
| Dec 29, 2017 | Upgrade Pro | Upgrade Pro |
| Dec 30, 2016 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| GlaxoSmithKline Pharmaceuticals | 359.26B |
| J. B. Chemicals & Pharmaceuticals | 355.66B |
| Rubicon Research | 213.43B |
| AstraZeneca Pharma India | 210.63B |
| Granules India | 185.61B |
| Jubilant Pharmova | 154.48B |
| Viyash Scientific | 109.03B |
| CORONA Remedies | 105.91B |